FO
FLNA

FT Options’s Filana Therapeutics FLNA Stock Holding History

FT Options’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-12,429
Closed -$128K – 354
2016
Q3 		$128K Buy
12,429
+1,715
+16% +$28.4K 0.1% 141
2016
Q2 		$56K Buy
+10,714
New +$170K 0.05% 196

Other funds holding FLNA

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
ZIM
Zacks Investment Management Chicago, Illinois $12.5B AUM 29.36% 1-Year Est. Return

FT Options's FLNA Position: Q4 2016 in Review

FT Options sold out of Filana Therapeutics (FLNA) in Q4 2016, closing a stake of 6,214 shares — an estimated $43K sold.

FT Options first reported a position in FLNA in Q2 2016 and held it in 2 quarters. The position peaked at $77K in Q2 2016. 46 funds tracked by Wall St. Rank hold FLNA as of Q4 2016.

  • FT Options reported no remaining Filana Therapeutics position as of Q4 2016 after selling out during the quarter.
  • FT Options sold 6,214 Filana Therapeutics shares in Q4 2016, an estimated $43K.
  • FT Options first reported a position in Filana Therapeutics in Q2 2016 and held it in 2 quarters.
  • FT Options's Filana Therapeutics position peaked at $77K in Q2 2016.
  • 46 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2016.

Based on FT Options's 13F filing for Q4 2016, filed 10 Feb 2017.